These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37486556)

  • 1. Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study.
    Zhao Q; Zheng B; Han B; Feng P; Xia Z; Jiang H; Ying Y; Zhu J; Fei C; Xiang J; Shen L; Luo Q; Wu Y; Wusiman A; Xin C; Zhang M; Li G; Li X
    Infect Dis Ther; 2023 Aug; 12(8):2087-2102. PubMed ID: 37486556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching.
    Wei AH; Zeng L; Wang L; Gui L; Zhang WT; Gong XP; Li J; Liu D
    Front Pharmacol; 2023; 14():1274294. PubMed ID: 37900159
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative analysis of the safety and effectiveness of Nirmatrelvir-Ritonavir and Azvudine in older patients with COVID-19: a retrospective study from a tertiary hospital in China.
    Shang N; Li X; Guo Z; Zhang L; Wang S
    Front Pharmacol; 2024; 15():1362345. PubMed ID: 39104387
    [No Abstract]   [Full Text] [Related]  

  • 4. Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study.
    Han X; Gao D; Li C; Yuan X; Cui J; Zhao W; Xie F; Wang K; Liu Y; Muo G; Xi N; Zheng M; Wang R; Xiao K; Zhao D; Zhang X; Han X; Wang B; Zhang T; Xie W; Xie L
    BMC Infect Dis; 2024 Jan; 24(1):57. PubMed ID: 38191304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study.
    Zhao X; Cheng Y; Zhang M; Qianda B; Zhouma B; Yangzhen B; Zheng Y; Zhang S; Zhao H
    Infect Drug Resist; 2023; 16():6053-6060. PubMed ID: 37719651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world study.
    Wang S; Sun J; Zhang X; Li M; Qin B; Liu M; Zhang N; Wang S; Zhou T; Zhang W; Ma C; Deng X; Bai Y; Qu G; Liu L; Shi H; Zhou B; Li K; Yang B; Li S; Wang F; Ma J; Zhang L; Wang Y; An L; Liu W; Chang Q; Zhang R; Yin X; Yang Y; Ao Q; Ma Q; Yan S; Huang H; Song P; Gao L; Lu W; Xu L; Lei L; Wang K; Zhang Q; Song Q; Zhang Z; Fang X; He Y; Li T; Zhu P
    EClinicalMedicine; 2024 Mar; 69():102468. PubMed ID: 38361990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study.
    Chen MP; Jiang DX; Rang JX; Zhuo HB; Zhou ZG
    Sci Rep; 2024 Feb; 14(1):3318. PubMed ID: 38337014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: A retrospective cohort study.
    Deng G; Li D; Sun Y; Jin L; Zhou Q; Xiao C; Wu Q; Sun H; Dian Y; Zeng F; Pan P; Shen M
    J Med Virol; 2023 Apr; 95(4):e28756. PubMed ID: 37185838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azvudine and nirmatrelvir-ritonavir in hospitalized patients with moderate-to-severe COVID-19: Emulation of a randomized target trial.
    Zhou Y; Liu Y; Jiang L; Zhang R; Zhang H; Shi Q; Yang Z; Mao Y; Liu S; Yang Z; Ding J; Zhou Y; Ren B; He L; Zhao X; Li W; Li S; Liu D
    J Med Virol; 2023 Dec; 95(12):e29318. PubMed ID: 38112106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Real-World Retrospective Study on the Efficacy and Safety of Four Antiviral Drugs for Hospitalized COVID-19 Patients: Nirmatrelvir/Ritonavir, Simnotrelvir/Ritonavir, Molnupiravir and Azvudine.
    Yu X; Luo R; Xie G; Ji J; Wang J; Li X; Qian X; Wang X
    Infect Drug Resist; 2024; 17():3967-3978. PubMed ID: 39296775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Azvudine and Nirmatrelvir/Ritonavir and Combined Use in Patients with COVID-19.
    Hu CY; Cui WS; Lei Y; Tang YW; Zhang YY; Su QM; Peng F; Zeng YF; Song JL; Luo CN; Zhou Y; Li XY; Zhao ZX
    Infect Drug Resist; 2023; 16():7797-7808. PubMed ID: 38148771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19: a retrospective observational study.
    Zhou Z; Zheng H; Xiao G; Xie X; Rang J; Peng D
    BMC Infect Dis; 2024 Jan; 24(1):47. PubMed ID: 38177982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of the antiviral medications azvudine and nirmatrelvir-ritonavir in treating COVID-19 in patients with hematological malignancies.
    Zeng Z; Li F; Zhong M; Zhu L; Chen W; Wang X
    Clinics (Sao Paulo); 2024; 79():100406. PubMed ID: 39059144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of nirmatrelvir-ritonavir versus azvudine for adult inpatients with severe or critical COVID-19.
    Zhang H; Xiaojiao T; Chen J; Zhang Z; Wang C; Shi H; Li Y; Li J; Kang Y; Jin X; Liao X
    BMJ Open Respir Res; 2024 Apr; 11(1):. PubMed ID: 38599779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of azvudine versus nirmatrelvir-ritonavir in adult patients infected with COVID-19 omicron strains: a retrospective study in Beijing.
    Xie H; Wang Y; Xu Y; Wang L; Fan J; Pan S; Shi C; Liu X; Gao X; Guo X; Yu S; Liu J; Zhang D; Yang Y; Zhang H; Wang J; Wu A; Liu X; Liu J; Zhu H; Zhou X; Tian X; Wang M
    Sci Rep; 2024 Oct; 14(1):23974. PubMed ID: 39402091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of safety and efficacy between Nirmatrelvir-ritonavir and molnupiravir in the treatment of COVID-19 infection in patients with advanced kidney disease: a retrospective observational study.
    Chu WM; Wan EYF; Ting Wong ZC; Tam AR; Kei Wong IC; Yin Chan EW; Ngai Hung IF
    EClinicalMedicine; 2024 Jun; 72():102620. PubMed ID: 38737003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Azvudine versus Paxlovid in COVID-19: A systematic review and meta-analysis.
    Amani B; Amani B
    Rev Med Virol; 2024 Jul; 34(4):e2551. PubMed ID: 38849982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations of nirmatrelvir-ritonavir treatment with death and clinical improvement in hospitalized patients with COVID-19 during the Omicron wave in Beijing, China: a multicentre, retrospective cohort study.
    Han X; Li C; Yuan X; Cui J; Han Z; Meng J; Zhao W; Xie F; Wang K; Liu Y; Muo G; Xi N; Zheng M; Wang R; Xiao K; Chen W; Xiong J; Zhao D; Zhang X; Han X; Cheng H; Yu Z; Shi Y; Xie W; Xie L
    Ann Med; 2024 Dec; 56(1):2313062. PubMed ID: 38354691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
    Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
    JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world effectiveness of molnupiravir, azvudine and paxlovid against mortality and viral clearance among hospitalized patients with COVID-19 infection during the omicron wave in China: A retrospective cohort study.
    Chen Y; Lin Y; Lu H; Wu X; Pan Y; Xia A; Pang L; Ye W; Xu F
    Diagn Microbiol Infect Dis; 2024 Aug; 109(4):116353. PubMed ID: 38776665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.